Allen K. Bourdon

Allen K. Bourdon

Auto-generated profile, based on publicly available information

Allen K. Bourdon

University of Tennessee at Knoxville, Knoxville, Tennessee, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2017 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JYJun Yan
Jun Yan
MBMeng Bi
Meng Bi
ABAllen K Bourdon
Allen K Bourdon
AFAbigail T Farmer
Abigail T Farmer
PWPo-Hsiang Wang
Po-Hsiang Wang
FLFrank E Löffler
Frank E Löffler

25 July 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ABAllen K. Bourdon
Allen K. Bourdon
GSGiovanna Maria Spano
Giovanna Maria Spano
WMWilliam Marshall
William Marshall
MBMichele Bellesi
Michele Bellesi
GTGiulio Tononi
Giulio Tononi
CCChiara Cirelli
Chiara Cirelli
By identifying endogenous molecules in brain extracellular fluid metabolomics can provide insight into the regulatory mechanisms and functions of sleep. Here we studied how the cortical metabolome changes during sleep, sleep deprivation and spontaneous wakefulness. Mice were implanted with electrodes for chronic sleep/wake recording and with microdialysis probes targeting prefrontal and primary motor cortex. Metabolites were measured using ultra performance liquid chromatography-high resolution mass spectrometry. Sleep/wake changes in metabolites were evaluated using partial least squares discriminant analysis, linear mixed effects model analysis of variance, and machine-learning algorithms. More than 30 known metabolites were reliably detected in most samples. When used by a logistic regression classifier, the profile of these metabolites across sleep, spontaneous wake, and enforced wake was sufficient to assign mice to their correct experimental group (pair-wise) in 80–100% of cases. Eleven of these metabolites showed significantly higher levels in awake than in sleeping mice. Some changes extend previous findings (glutamate, homovanillic acid, lactate, pyruvate, tryptophan, uridine), while others are novel (D-gluconate, N-acetyl-beta-alanine, N-acetylglutamine, orotate, succinate/methylmalonate). The upregulation of the de novo pyrimidine pathway, gluconate shunt and aerobic glycolysis may reflect a wake-dependent need to promote the synthesis of many essential components, from nucleic acids to synaptic membranes.

4 June 2018 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
HLHuiyun Liang
Huiyun Liang
ABAllen K. Bourdon
Allen K. Bourdon
LCLiao Chen
Liao Chen
CPClyde F. Phelix
Clyde F. Phelix
George PerryGeorge Perry
George Perry
Fourteen glucose transporters (GLUTs) play essential roles in human physiology by facilitating glucose diffusion across the cell membrane. Due to its central role in the energy metabolism of the central nervous system, GLUT3 has been thoroughly investigated. However, the Gibbs free-energy gradient (what drives the facilitated diffusion of glucose) has not been mapped out along the transport path. Some fundamental questions remain. Here we present a molecular dynamics study of GLUT3 embedded in a lipid bilayer to quantify the free-energy profile along the entire transport path of attracting a β-D-glucose from the interstitium to the inside of GLUT3 and, from there, releasing it to the cytoplasm by Arrhenius thermal activation. From the free-energy profile, we elucidate the unique Michaelis-Menten characteristics of GLUT3, low KM and high VMAX, specifically suitable for neurons’ high demand of energy from their low-glucose environments. We compute GLUT3’s binding free energy for β-D-glucose to be -4.6 kcal/mol in agreement with the experimental value of -4.4 kcal/mol (KM=1.4 mM). We also compute the hydration energy of β-D-glucose, -18.0 kcal/mol vs. the experimental data, -17.8 kcal/mol. In this, we establish a dynamics-based connection from GLUT3’s crystal structure to its cellular thermodynamics with quantitative accuracy. We predict equal Arrhenius barriers for glucose uptake and efflux through GLUT3 to be tested in future experiments.

1 December 2020 in Journal of Neurophysiology
Verified
Journal Article
Closed access
PDF file
ABAaron G. Baer
Aaron G. Baer
ABAllen K. Bourdon
Allen K. Bourdon
JPJoshua M. Price
Joshua M. Price
SCShawn R. Campagna
Shawn R. Campagna
DJDaniel Jacobson
Daniel Jacobson
RLRalph Lydic
Ralph Lydic
Identifying similarities and differences in the brain metabolome during different states of consciousness has broad relevance for neuroscience and state-dependent autonomic function. This study focused on the prefrontal cortex (PFC) as a brain region known to modulate states of consciousness. Anesthesia was used as a tool to eliminate wakefulness. Untargeted metabolomic analyses were performed on microdialysis samples obtained from mouse PFC during wakefulness and during isoflurane anesthesia. Analyses detected 2,153 molecules, 91 of which could be identified. Analytes were grouped as detected during both wakefulness and anesthesia (n = 61) and as unique to wakefulness (n = 23) or anesthesia (n = 7). Data were analyzed using univariate and multivariate approaches. Relative to wakefulness, during anesthesia there was a significant (q < 0.0001) fourfold change in 21 metabolites. During anesthesia 11 of these 21 molecules decreased and 10 increased. The Kyoto Encyclopedia of Genes and Genomes database was used to relate behavioral state-specific changes in the metabolome to metabolic pathways. Relative to wakefulness, most of the amino acids and analogs measured were significantly decreased during isoflurane anesthesia. Nucleosides and analogs were significantly increased during anesthesia. Molecules associated with carbohydrate metabolism, maintenance of lipid membranes, and normal cell functions were significantly decreased during anesthesia. Significant state-specific changes were also discovered among molecules comprising lipids and fatty acids, monosaccharides, and organic acids. Considered together, these molecules regulate point-to-point transmission, volume conduction, and cellular metabolism. The results identify a novel ensemble of candidate molecules in PFC as putative modulators of wakefulness and the loss of wakefulness. NEW & NOTEWORTHY The loss of wakefulness caused by a single concentration of isoflurane significantly altered levels of interrelated metabolites in the prefrontal cortex. The results support the interpretation that states of consciousness reflect dynamic interactions among cortical neuronal networks involving a humbling number of molecules that comprise the brain metabolome.

1 July 2017 in International Journal of Knowledge Discovery in Bioinformatics
Verified
Journal Article
Closed access
PDF file
JDJason L. Dugan
Jason L. Dugan
ABAllen K. Bourdon
Allen K. Bourdon
CPClyde F. Phelix
Clyde F. Phelix
The plant and human mitochondrial pyruvate carrier (MPC) had been studied in the 1970s-1990s providing many predictions on functional protein structure and mechanisms of substrate binding. Genes for human and plant MPC have been identified, but no crystal structure has yet been registered or deposited in a protein data bank. This report describes results for comparisons of structure for human and plant MPC1/2 heterodimer homology models. Key cysteine residues are identified for pyruvate and blocker binding and formation of thiohemiacetal or Michael addition bonds. Evidence is provided for an alternating access model in human, mouse ear-cress, castor and common beans, and corn.

1 July 2017 in International Journal of Knowledge Discovery in Bioinformatics
Verified
Journal Article
Closed access
PDF file
CPClyde F. Phelix
Clyde F. Phelix
ABAllen K. Bourdon
Allen K. Bourdon
JDJason L. Dugan
Jason L. Dugan
GVGreg Villareal
Greg Villareal
George PerryGeorge Perry
George Perry
The mitochondrial pyruvate carrier (MPC) is a novel target for therapeutic drugs to treat Alzheimer's and Parkinson's disease, diabetes mellitus, and non-alcoholic steatohepatitis (NASH). Metabolic Solutions Development Company (MSDC) has two thiazolidinediones, MSDC-0160 and MSDC-0602, in the pipeline. This report describes results for a MPC1/2 heterodimer homology model. The FASTA sequences for MPC1 and MPC2 were accessed from UniProt and submitted to RaptorX, resulting in best candidate monomeric “protein data base” files for each. One mutant form of MPC1, L36I, was also processed. These were submitted to PyDock to generate best candidate MPC1/2 heterodimer models that were used for ligand docking analyses with AutoDock Vina and “Rosetta Online Server that Includes Everyone” (ROSIE). Multiple binding sites for pyruvate and both drugs were found on both MPC1 and MPC2 subunits with drugs having nearly double the affinity in each case except the intermediate and open-in states for the L36I mutant transporter.